AgeX Therapeutics CEO Michael D. West, Ph.D. to Deliver Keynote Address on Biotechnology and Aging at RAAD Festival
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 9, 2017--
AgeX Therapeutics, Inc. (AgeX),
a subsidiary of BioTime,
Inc. (NYSE MKT:BTX), announced today that CEO Michael D. West,
Ph.D., will deliver the keynote presentation at the RAAD Festival 2017 (RAADfest),
a large annual gathering of life extension experts, August 9-13, at the
Town and Country Resort & Convention Center in San Diego, California.
Dr. West will deliver the presentation titled “Telomeres,
Stem Cells, and iTR: Redefining Human Aging” on Wednesday, August 9th
at 7:00pm PDT. The presentation will be made available on the Company’s website.
About AgeX Therapeutics
AgeX Therapeutics, a subsidiary of BioTime, Inc. (NYSE MKT:BTX), is a
biotechnology company applying technology relating to cell immortality
and regenerative biology, to aging and age-related diseases. The company
will initially focus on three initial areas of product development:
pluripotent stem cell-derived brown adipocytes (AGEX-BAT1); vascular
progenitors (AGEX-VASC1); and induced Tissue Regeneration (iTR). Initial
planned indications for these products are Type 2 diabetes, cardiac
ischemia, and cancer, respectively. More information on AgeX can be
found on the company’s
BioTime is a clinical-stage biotechnology company focused on developing
and commercializing products addressing degenerative diseases. Its
clinical programs are based on two platform technologies: pluripotent
cells and cell/drug delivery. The foundation of BioTime’s core
therapeutic technology platform is pluripotent cells that are capable of
becoming any of the cell types in the human body. The foundation of the
Company’s cell delivery platform is its HyStem® cell and drug delivery
matrix technology. The Company’s current clinical programs are targeting
three primary sectors, aesthetics, ophthalmology and cell/drug delivery.
BioTime also has significant equity holdings in two publicly traded
companies, Asterias Biotherapeutics, Inc. (“Asterias”) and OncoCyte
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com
or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com.
Certain statements contained in this release are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Statements pertaining to future financial and/or
operating results, future growth in research, technology, clinical
development, and potential opportunities for BioTime, Inc. and its
subsidiaries, along with other statements about the future expectations,
beliefs, goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical fact
(including, but not limited to statements that contain words such as
“will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”
should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including,
without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with
the many uncertainties that affect the business of BioTime, Inc. and its
subsidiaries, particularly those mentioned in the cautionary statements
found in more detail in the “Risk Factors” section of its Annual Reports
on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC
(copies of which may be obtained at www.sec.gov).
Subsequent events and developments may cause these forward-looking
statements to change. BioTime specifically disclaims any obligation or
intention to update or revise these forward-looking statements as a
result of changed events or circumstances that occur after the date of
this release, except as required by applicable law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170809005364/en/
Source: BioTime, Inc.
Investor Contact for BioTime:
EVC Group, Inc.
Contact for AgeX:
Bill Douglass, 646-504-0890